PE20060332A1 - Derivados de 1,6-naftiridina y 1,8-naftiridina para el tratamiento de la diabetes y trastornos relacionados - Google Patents

Derivados de 1,6-naftiridina y 1,8-naftiridina para el tratamiento de la diabetes y trastornos relacionados

Info

Publication number
PE20060332A1
PE20060332A1 PE2005000284A PE2005000284A PE20060332A1 PE 20060332 A1 PE20060332 A1 PE 20060332A1 PE 2005000284 A PE2005000284 A PE 2005000284A PE 2005000284 A PE2005000284 A PE 2005000284A PE 20060332 A1 PE20060332 A1 PE 20060332A1
Authority
PE
Peru
Prior art keywords
alkyl
diabetes
naphthyridine
naphthyridin
phenyl
Prior art date
Application number
PE2005000284A
Other languages
English (en)
Inventor
Rainer Heurich
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of PE20060332A1 publication Critical patent/PE20060332A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE 1,6-NAFTIRIDA O 1,8-NAFTIRIDA DE FORMULA I DONDE R1 ES ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, ENTRE OTROS; R2 ES NR15R16, S(O)0-2R17, ENTRE OTROS; R15 ES H, ALQUILO C1-C6, ALQUENILO C2-C6; R16 ES ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C6, ENTRE OTROS; R3 ES ARILO C6-C10, HETEROARILO DE 2 A 9 ATOMOS DE CARBONO Y 1 A 4 HETEROATOMOS SELECCIONADOS DE N, S(=O)0-2 Y O, ENTRE OTROS; R4 ES =O, =S Y OR21; R21 ES H, ALQUILO C1-C8, ALQUENILO C2-C8, ENTRE OTROS; R5 Y R6 SON CICLOLAQUILO C3-C8, CICLOALQUENILO C4-C8, ENTRE OTROS; R7 ES CICLOALQUILO C3-C8, CICLOALQUENILO C4-C8, ARILO C6-C10, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-ANILINO-5-METIL-1-FENIL-1,8-NAFTIRIDIN-4(1H)-ONA, 5-METIL-7-MORFOLIN-4-IL-1-FENIL-2-FENILAMINO-1H-[1,8]-NAFTIRIDIN-4-ONA, 5-METIL-1-FENIL-2,7-BIS-FENILAMINO-1H-[1,8]NAFTIRIDIN-4-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A COMPOSICIONES QUE COMPRENDEN DICHO COMPUESTO, EL CUAL ES UTIL EN EL TRATAMIENTO O PREVENCION DE LA DIABETES (TIPO 1 O 2), DIABETES JUVENIL DE INICIO EN LA MADUREZ, DIABETES AUTOINMUNE DEL ADULTO, INTOLERANCIA A LA GLUCOSA, GLUCEMIA BASAL ALTERADA, DIABETES GESTACIONAL Y SINDROME METABOLICO X
PE2005000284A 2004-03-12 2005-03-11 Derivados de 1,6-naftiridina y 1,8-naftiridina para el tratamiento de la diabetes y trastornos relacionados PE20060332A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55297104P 2004-03-12 2004-03-12

Publications (1)

Publication Number Publication Date
PE20060332A1 true PE20060332A1 (es) 2006-06-01

Family

ID=35056657

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000284A PE20060332A1 (es) 2004-03-12 2005-03-11 Derivados de 1,6-naftiridina y 1,8-naftiridina para el tratamiento de la diabetes y trastornos relacionados

Country Status (6)

Country Link
AR (1) AR048088A1 (es)
GT (1) GT200500049A (es)
PE (1) PE20060332A1 (es)
TW (1) TW200538124A (es)
UY (1) UY28805A1 (es)
WO (1) WO2005091857A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015917A2 (en) * 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US20130197043A1 (en) 2010-08-31 2013-08-01 Snu R&Db Foundation Use of the fetal reprogramming of a ppar agonist
EP3660016A1 (en) 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
CN103649053B (zh) * 2011-07-12 2017-07-04 霍夫曼-拉罗奇有限公司 氨基甲基喹诺酮化合物
SG11201400232WA (en) 2011-09-02 2014-03-28 Incyte Corp Heterocyclylamines as pi3k inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
EP3262046B1 (en) 2015-02-27 2020-11-04 Incyte Corporation Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2018102885A1 (en) * 2016-12-09 2018-06-14 Bionomics Limited Modulators of nicotinic acetylcholine receptors and uses thereof
JOP20180097B1 (ar) * 2018-10-22 2023-03-28 Univ Of Jordan مشتقات 1.8 - نفثاريدين الغلايكوزيلية و طرق تحضيرها و استخدامها في معالجة الالتهابات الميكروبية

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL51092A0 (en) * 1976-12-10 1977-02-28 Abic Ltd Naphthyridine derivatives and their preparation
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials

Also Published As

Publication number Publication date
AR048088A1 (es) 2006-03-29
GT200500049A (es) 2005-10-24
WO2005091857A3 (en) 2006-10-05
UY28805A1 (es) 2005-09-30
WO2005091857A2 (en) 2005-10-06
TW200538124A (en) 2005-12-01

Similar Documents

Publication Publication Date Title
PE20060332A1 (es) Derivados de 1,6-naftiridina y 1,8-naftiridina para el tratamiento de la diabetes y trastornos relacionados
PE20110383A1 (es) Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
PE20030601A1 (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados
PE20070498A1 (es) Compuestos derivados de indoles de acilo como antagonistas del receptor de glucagon
RU2403253C2 (ru) Пуриновые производные для применения в качестве агонистов аденозинового рецептора а-2а
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
CO5700726A2 (es) Compuestos organicos
ES2530431T3 (es) Compuestos heterocíclicos como moduladores positivos del receptor de glutamato metabotrópico 2 (receptor mGlu2)
CO6180449A2 (es) Quinazolinonas y naftiridinonas que incluyen un grupo n-(bifenil-4-ilmetil-n-(piperidin-4-il)acetamida sustituida, utiles para el tratamiento de aterosclerosis
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
AR065276A1 (es) Herbicidas de n-oxidos de piridina sustituidos
PE20060833A1 (es) Derivados de purina como agonistas del receptor a2a de adenosina
PE20071328A1 (es) Compuestos de heteroarilo biciclico que contienen nitrogeno y metodos de uso
CO6160266A2 (es) Derivado de oxopirazina y herbicida
PE20060886A1 (es) Composicion fungicida a base de un derivado de carboxamida triciclico
DE602005005167D1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR061644A1 (es) Derivados de benzofurano
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen
ATE430746T1 (de) Crf-rezeptor-antagonisten und zugehörige verfahren
PE20090484A1 (es) Moduladores de calicreina 7
ATE532834T1 (de) Pigmentdispersion und tintenzusammensetzung, die diese verwendet
BRPI0619894B8 (pt) composto de amina e composição farmacêutica
ECSP088926A (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina
PE20000134A1 (es) Arilpiperazinas que tienen actividad sobre el receptor 1a de la serotonina

Legal Events

Date Code Title Description
FC Refusal